Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study Meeting Abstract
| Authors: | O'Cearbhaill, R. E.; Moore, K. N.; Yeku, O.; Liu, J. F.; Bouberhan, S.; Hamilton, E. P.; Hou, J. Y.; Van Nieuwenhuysen, E.; Papadimitriou, K.; Yoo, S. Y.; Govindraj, S.; Brouwer-Visser, J.; Peterman, M.; Schmidt, T.; Barnes, B.; Madia, P.; Zhu, M.; Uldrick, T. S.; Miller, E. A.; O'Malley, D. |
| Abstract Title: | Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S516 |
| End Page: | S517 |
| Language: | English |
| ACCESSION: | WOS:001087480201095 |
| DOI: | 10.1016/j.annonc.2023.09.1933 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 754P -- Source: Wos |
